Acute hepatic cytolysis in an HIV-infected patient taking atazanavir [3]

AIDS

Volumn 18, Issue 11, 2004, Pages 1610-1611

  Eholié, Serge P ^a   Lacombe, Karine ^a   Serfaty, Lawrence ^a   Wendum, Dominique ^a   Girard, Pierre Marie ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; STAVUDINE; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; CYTOLYSIS; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LETTER; LIVER CELL DAMAGE; MULTIDRUG RESISTANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ACUTE DISEASE; FEMALE; HEPATITIS, TOXIC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES;

EID: 3843113309     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131369.90575.9e     Document Type: Letter

References (8)

1. Wang S, Mulvey R, Laing J, Leet J, Flint O, Parker RA. Differentiation of atazanavir from other HIV protease inhibitors in preclinical models of glucose uptake, lipogenesis and protease function. In: 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, CA, 2002 [Abstract published in Antiviral Therapy 7:L6, 2002].
2. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1331-1336.
3. Division of AIDS, National of Institute Allergy and Infectious Diseases. Division of AIDS table for grading severity of adult adverse experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 1996.
4. Arribas JR, Ibanez C, Antoran-Ruiz B, Pena JM, Esteban-Calvo C, Frias J, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998, 12:1722-1724.
5. Vergis E, Paterson DL, Singh N. Indinavir associated hepatitis in patients with advanced HIV infection. Int J STD AIDS 1998, 9:53.
6. Wit WNMF, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence of and risk factors for severe hepatoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186:23-31.
7. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV infected patient on protease inhibitor. Lancet 349:995-996.
8. Savès M, Raffi F, Clevenbergh, Marchou B, Waldner-Combernoux A, Morlat P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus infected patients. Antimicrob Agents Chemother 2000, 12:3451-3455.